Polypoidal choroidal vasculopathy in Asians

Journal of Clinical Medicine

Volumn 4, Issue 5, 2015, Pages 782-821

  Wong, Chee Wai ^a,b   Wong, Tien Y ^a,b   Cheung, Chui Ming Gemmy ^a,b  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anti vascular endothelial growth factor; Asians; Epidemiology; Genetics; Photodynamic therapy; Polypoidal choroidal vasculopathy; Risk factors

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; MATRIX METALLOPROTEINASE;

AGE RELATED MACULAR DEGENERATION; ANGIOGRAPHY; CENTRAL SEROUS RETINOPATHY; EXTRACELLULAR MATRIX; HUMAN; LASER COAGULATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHARMACOGENETICS; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; REVIEW; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; SUBRETINAL NEOVASCULARIZATION;

EID: 84944468987     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4050782     Document Type: Review

References (227)

1. Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.; Wong, T.Y. Age-related macular degeneration. Lancet 2012, 379, 1728–1738.
2. Chakravarthy, U.; Wong, T.Y.; Fletcher, A.; Piault, E.; Evans, C.; Zlateva, G.; Buggage, R.; Pleil, A.; Mitchell, P. Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis. BMC Ophthalmol. 2010, 10, doi:10.1186/1471-2415-10-31.
3. Klein, R.; Klein, B.E.; Knudtson, M.D.; Wong, T.Y.; Cotch, M.F.; Liu, K.; Burke, G.; Saad, M.F.; Jacobs, D.R., Jr. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006, 113, 373–380.
4. Lim, L.S.; Cheung, C.M.G.; Wong, T.Y. Asian age-related macular degeneration: Current concepts and gaps in knowledge. Asia Pac. J. Ophthalmol. 2013, 2, 32–41.
5. Laude, A.; Cackett, P.D.; Vithana, E.N.; Yeo, I.Y.; Wong, D.; Koh, A.H.; Wong, T.Y.; Aung, T. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Progr. Retin. Eye Res. 2010, 29, 19–29.
6. Cheung, C.M.; Wong, T.Y. Ranibizumab and bevacizumab for AMD. N. Engl. J. Med. 2011, 365, 2237.
7. Wong, T.Y.; Zheng, Y.; Jonas, J.B.; Flaxman, S.R.; Keeffe, J.; Leasher, J.; Naidoo, K.; Pesudovs, K.; Price, H.; White, R.A.; et al. Prevalence and causes of vision loss in east asia: 1990–2010. Br. J. Ophthalmol. 2014, 98, 599–604.
8. Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet. Glob. Health 2014, 2, e106–e116.
9. Yasuda, M.; Kiyohara, Y.; Hata, Y.; Arakawa, S.; Yonemoto, K.; Doi, Y.; Iida, M.; Ishibashi, T. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama Study. Ophthalmology 2009, 116, 2135–2140.
10. You, Q.S.; Xu, L.; Yang, H.; Li, Y.B.; Wang, S.; Wang, J.D.; Zhang, J.S.; Wang, Y.X.; Jonas, J.B. Five-year incidence of age-related macular degeneration: The Beijing Eye Study. Ophthalmology 2012, 119, 2519–2525.
11. La, T.Y.; Cho, E.; Kim, E.C.; Kang, S.; Jee, D. Prevalence and risk factors for age-related macular degeneration: Korean national health and nutrition examination survey 2008–2011. Curr. Eye Res. 2014, 39, 1232–1239.
12. Cho, B.J.; Heo, J.W.; Kim, T.W.; Ahn, J.; Chung, H. Prevalence and risk factors of age-related macular degeneration in korea: The Korea national health and nutrition examination survey 2010–2011. Investig. Ophthalmol. Vis. Sci. 2014, 55, 1101–1108.
13. Chen, S.J.; Cheng, C.Y.; Peng, K.L.; Li, A.F.; Hsu, W.M.; Liu, J.H.; Chou, P. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: The Shihpai Eye Study. Investig. Ophthalmol. Vis. Sci. 2008, 49, 3126–3133.
14. Li, Y.; Xu, L.; Jonas, J.B.; Yang, H.; Ma, Y.; Li, J. Prevalence of age-related maculopathy in the adult population in China: The beijing eye study. Am. J. Ophthalmol. 2006, 142, 788–793.
15. Huang, E.J.; Wu, S.H.; Lai, C.H.; Kuo, C.N.; Wu, P.L.; Chen, C.L.; Chen, C.Y.; King, Y.C.; Wu, P.C. Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: The Puzih Eye Study. Eye 2014, 28, 705–714.
16. Oshima, Y.; Ishibashi, T.; Murata, T.; Tahara, Y.; Kiyohara, Y.; Kubota, T. Prevalence of age related maculopathy in a representative japanese population: The Hisayama Study. Br. J. Ophthalmol. 2001, 85, 1153–1157.
17. Oguido, A.P.; Casella, A.M.; Matsuo, T.; Ramos Filho, E.H.; Berbel, R.; Silva, R.M. Prevalence of age-related macular degeneration in Japanese immigrants and their descendants living in Londrina (pr)—Brazil. Arquivos brasileiros de oftalmologia 2008, 71, 375–380.
18. Ye, H.; Zhang, Q.; Liu, X.; Cai, X.; Yu, W.; Yu, S.; Wang, T.; Lu, W.; Li, X.; Jin, H.; et al. Prevalence of age-related macular degeneration in an elderly urban Chinese population in China: The jiangning eye study. Investig. Ophthalmol. Vis. Sci. 2014, 55, 6374–6380.
19. Yang, K.; Liang, Y.B.; Gao, L.Q.; Peng, Y.; Shen, R.; Duan, X.R.; Friedman, D.S.; Sun, L.P.; Mitchell, P.; Wang, N.L.; et al. Prevalence of age-related macular degeneration in a rural Chinese population: The Handan Eye Study. Ophthalmology 2011, 118, 1395–1401.
20. Stein, J.D.; Vanderbeek, B.L.; Talwar, N.; Nan, B.; Musch, D.C.; Zacks, D.N. Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups. Investig. Ophthalmol. Vis. Sci. 2011, 52, 6842–6848.
21. Song, S.J.; Youm, D.J.; Chang, Y.; Yu, H.G. Age-related macular degeneration in a screened South Korean population: Prevalence, risk factors, and subtypes. Ophthalmic Epidemiol. 2009, 16, 304–310.
22. Kawasaki, R.; Wang, J.J.; Ji, G.J.; Taylor, B.; Oizumi, T.; Daimon, M.; Kato, T.; Kawata, S.; Kayama, T.; Tano, Y.; et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: The Funagata Study. Ophthalmology 2008, 115, 1376–1381.
23. Jenchitr, W.; Ruamviboonsuk, P.; Sanmee, A.; Pokawattana, N. Prevalence of age-related macular degeneration in Thailand. Ophthalmic Epidemiol. 2011, 18, 48–52.
24. Chang, Y.C.; Wu, W.C. Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg. Lasers Imaging 2009, 40, 576–581.
25. Wen, F.; Chen, C.; Wu, D.; Li, H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242, 625–629.
26. Liu, Y.; Wen, F.; Huang, S.; Luo, G.; Yan, H.; Sun, Z.; Wu, D. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245, 1441–1445.
27. Sho, K.; Takahashi, K.; Yamada, H.; Wada, M.; Nagai, Y.; Otsuji, T.; Nishikawa, M.; Mitsuma, Y.; Yamazaki, Y.; Matsumura, M.; et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch. Ophthalmol. 2003, 121, 1392–1396.
28. Coscas, G.; Yamashiro, K.; Coscas, F.; de Benedetto, U.; Tsujikawa, A.; Miyake, M.; Wong, T.Y.; Gemmy Cheung, C.M.; Yoshimura, N. Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: Multicenter diagnosis with multimodal imaging. Am. J. Ophthalmol. 2014, 158, 309–318.
29. Maruko, I.; Iida, T.; Saito, M.; Nagayama, D.; Saito, K. Clinical characteristics of exudative age-related macular degeneration in japanese patients. Am. J. Ophthalmol. 2007, 144, 15–22.
30. Byeon, S.H.; Lee, S.C.; Oh, H.S.; Kim, S.S.; Koh, H.J.; Kwon, O.W. Incidence and clinical patterns of polypoidal choroidal vasculopathy in korean patients. Jpn. J. Ophthalmol. 2008, 52, 57–62.
31. Cheung, C.M.; Li, X.; Mathur, R.; Lee, S.Y.; Chan, C.M.; Yeo, I.; Loh, B.K.; Williams, R.; Wong, E.Y.; Wong, D.; et al. A prospective study of treatment patterns and 1-year outcome of asian age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS ONE 2014, 9, e101057.
32. Mori, K.; Horie-Inoue, K.; Gehlbach, P.L.; Takita, H.; Kabasawa, S.; Kawasaki, I.; Ohkubo, T.; Kurihara, S.; Iizuka, H.; Miyashita, Y.; et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology 2010, 117, 928–938.
33. Ciardella, A.P.; Donsoff, I.M.; Huang, S.J.; Costa, D.L.; Yannuzzi, L.A. Polypoidal choroidal vasculopathy. Surv. Ophthalmol. 2004, 49, 25–37.
34. Li, Y.; You, Q.S.; Wei, W.B.; Xu, J.; Chen, C.X.; Wang, Y.X.; Xu, L.; Jonas, J.B. Polypoidal choroidal vasculopathy in adult Chinese: The Beijing Eye Study. Ophthalmology 2014, 121, 2 290–2291.
35. Cheung, C.M.; Li, X.; Cheng, C.Y.; Zheng, Y.; Mitchell, P.; Wang, J.J.; Wong, T.Y. Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays. Ophthalmology 2014, 121, 1598–1603.
36. Cackett, P.; Yeo, I.; Cheung, C.M.; Vithana, E.N.; Wong, D.; Tay, W.T.; Tai, E.S.; Aung, T.; Wong, T.Y. Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology 2011, 118, 846–852.
37. Cho, B.J.; Heo, J.W.; Shin, J.P.; Ahn, J.; Kim, T.W.; Chung, H. Epidemiological association between systemic diseases and age-related macular degeneration: The Korea national health and nutrition examination survey 2008–2011. Investig. Ophthalmol. Vis. Sci. 2014, 55, 4430–4437.
38. Kim, E.C.; Han, K.; Jee, D. Inverse relationship between high blood 25-hydroxyvitamin D and late stage of age-related macular degeneration in a representative Korean population. Investig. Ophthalmol. Vis. Sci. 2014, 55, 4823–4831.
39. Hahn, P.; Acquah, K.; Cousins, S.W.; Lee, P.P.; Sloan, F.A. Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries. Retina 2013, 33, 911–919.
40. Sakurada, Y.; Yoneyama, S.; Imasawa, M.; Iijima, H. Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina 2013, 33, 841–845.
41. Frank, R.N. Diabetes, diabetic retinopathy, and age-related macular degeneration: An unexpected relationship. Retina 2013, 33, 899–900.
42. Kikuchi, M.; Nakamura, M.; Ishikawa, K.; Suzuki, T.; Nishihara, H.; Yamakoshi, T.; Nishio, K.; Taki, K.; Niwa, T.; Hamajima, N.; et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 2007, 114, 1722–1727.
43. Beatty, S.; Koh, H.; Phil, M.; Henson, D.; Boulton, M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45, 115–134.
44. Solberg, Y.; Rosner, M.; Belkin, M. The association between cigarette smoking and ocular diseases. Surv. Ophthalmol. 1998, 42, 535–547.
45. Hammond, B.R., Jr.; Wooten, B.R.; Snodderly, D.M. Cigarette smoking and retinal carotenoids: Implications for age-related macular degeneration. Vis. Res. 1996, 36, 3003–3009.
46. Hammond, B.R., Jr.; Caruso-Avery, M. Macular pigment optical density in a Southwestern sample. Investig. Ophthalmol. Vis. Sci. 2000, 41, 1492–1497.
47. Suner, I.J.; Espinosa-Heidmann, D.G.; Marin-Castano, M.E.; Hernandez, E.P.; Pereira-Simon, S.; Cousins, S.W. Nicotine increases size and severity of experimental choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 2004, 45, 311–317.
48. Ueta, T.; Obata, R.; Inoue, Y.; Iriyama, A.; Takahashi, H.; Yamaguchi, T.; Tamaki, Y.; Yanagi, Y. Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2009, 116, 2400–2406.
49. Pawlak, K.; Mysliwiec, M.; Pawlak, D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine 2008, 43, 98–101.
50. Pawlak, K.; Pawlak, D.; Mysliwiec, M. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin. Biochem. 2007, 40, 81–85.
51. Kubisz, P.; Chudy, P.; Stasko, J.; Galajda, P.; Holly, P.; Vysehradsky, R.; Mokan, M. Circulating vascular endothelial growth factor in the normo-and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol. 2010, 47, 119–124.
52. Mahdy, R.A.; Nada, W.M.; Hadhoud, K.M.; El-Tarhony, S.A. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye 2010, 24, 1576–1584.
53. Tong, J.P.; Chan, W.M.; Liu, D.T.; Lai, T.Y.; Choy, K.W.; Pang, C.P.; Lam, D.S. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 2006, 141, 456–462.
54. Vine, A.K.; Stader, J.; Branham, K.; Musch, D.C.; Swaroop, A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005, 112, 2076–2080.
55. Wu, K.H.; Tan, A.G.; Rochtchina, E.; Favaloro, E.J.; Williams, A.; Mitchell, P.; Wang, J.J. Circulating inflammatory markers and hemostatic factors in age-related maculopathy: A population-based case-control study. Investig. Ophthalmol. Vis. Sci. 2007, 48, 1983–1988.
56. Klein, R.; Klein, B.E.; Knudtson, M.D.; Wong, T.Y.; Shankar, A.; Tsai, M.Y. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am. J. Ophthalmol. 2005, 140, 35–44.
57. Boey, P.Y.; Tay, W.T.; Lamoureux, E.; Tai, E.S.; Mitchell, P.; Wang, J.J.; Saw, S.M.; Wong, T.Y. C-reactive protein and age-related macular degeneration and cataract: The Singapore Malay Eye Study. Investig. Ophthalmol. Vis. Sci. 2010, 51, 1880–1885.
58. Schaumberg, D.A.; Christen, W.G.; Buring, J.E.; Glynn, R.J.; Rifai, N.; Ridker, P.M. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch. Ophthalmol. 2007, 125, 300–305.
59. Hogg, R.E.; Woodside, J.V.; Gilchrist, S.E.; Graydon, R.; Fletcher, A.E.; Chan, W.; Knox, A.; Cartmill, B.; Chakravarthy, U. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008, 115, 1046–1052.
60. Hong, T.; Tan, A.G.; Mitchell, P.; Wang, J.J. A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv. Ophthalmol. 2011, 56, 184–194.
61. Cheng, H.C.; Liu, J.H.; Lee, S.M.; Lin, P.K. Hyperhomocysteinemia in patients with polypoidal choroidal vasculopathy: A case control study. PLoS ONE 2014, 9, e110818.
62. McCully, K.S. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann. Clin. Lab. Sci. 2009, 39, 219–232.
63. Clarke, R.; Daly, L.; Robinson, K.; Naughten, E.; Cahalane, S.; Fowler, B.; Graham, I. Hyperhomocysteinemia: An independent risk factor for vascular disease. N. Engl. J. Med. 1991, 324, 1149–1155.
64. Seshadri, S.; Beiser, A.; Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; D’Agostino, R.B.; Wilson, P.W.; Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N. Engl. J. Med. 2002, 346, 476–483.
65. Rochtchina, E.; Wang, J.J.; Flood, V.M.; Mitchell, P. Elevated serum homocysteine, low serum vitamin B12, folate, and age-related macular degeneration: The Blue Mountains Eye Study. Am. J. Ophthalmol. 2007, 143, 344–346.
66. Nakashizuka, H.; Mitsumata, M.; Okisaka, S.; Shimada, H.; Kawamura, A.; Mori, R.; Yuzawa, M. Clinicopathologic findings in polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 2008, 49, 4729–4737.
67. Raffetto, J.D.; Khalil, R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75, 346–359.
68. Chong, N.H.; Keonin, J.; Luthert, P.J.; Frennesson, C.I.; Weingeist, D.M.; Wolf, R.L.; Mullins, R.F.; Hageman, G.S. Decreased thickness and integrity of the macular elastic layer of bruch’s membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am. J. Pathol. 2005, 166, 241–251.
69. Jones, A.; Kumar, S.; Zhang, N.; Tong, Z.; Yang, J.H.; Watt, C.; Anderson, J.; Amrita; Fillerup, H.; McCloskey, M.; et al. Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice. Proc. Natl. Acad. Sci. USA 2011, 108, 14578–14583.
70. Chau, K.Y.; Sivaprasad, S.; Patel, N.; Donaldson, T.A.; Luthert, P.J.; Chong, N.V. Plasma levels of matrix metalloproteinase-2 and-9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye 2008, 22, 855–859.
71. Zeng, R.; Wen, F.; Zhang, X.; Su, Y. Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration. Mol. Vis. 2013, 19, 729–736.
72. Xu, L.; You, Q.S.; Cui, T.; Jonas, J.B. Association between asymmetry in cataract and asymmetry in age-related macular degeneration. The Beijing Eye Study. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249, 981–985.
73. Sun, H.P.; Lin, Y.; Pan, C.W. Iris color and associated pathological ocular complications: A review of epidemiologic studies. Int. J. Ophthalmol. 2014, 7, 872–878.
74. Kim, S.W.; Oh, J.; Kwon, S.S.; Yoo, J.; Huh, K. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 2011, 31, 1904–1911.
75. Jirarattanasopa, P.; Ooto, S.; Nakata, I.; Tsujikawa, A.; Yamashiro, K.; Oishi, A.; Yoshimura, N. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 2012, 53, 3663–3672.
76. Koizumi, H.; Yamagishi, T.; Yamazaki, T.; Kawasaki, R.; Kinoshita, S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249, 1123–1128.
77. Rishi, P.; Rishi, E.; Mathur, G.; Raval, V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normals. Eye 2013, 27, 1038–1043.
78. Chung, S.E.; Kang, S.W.; Lee, J.H.; Kim, Y.T. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011, 118, 840–845.
79. Yannuzzi, L.A.; Freund, K.B.; Goldbaum, M.; Scassellati-Sforzolini, B.; Guyer, D.R.; Spaide, R.F.; Maberley, D.; Wong, D.W.; Slakter, J.S.; Sorenson, J.A.; et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000, 107, 767–777.
80. Park, H.S.; Kim, I.T. Clinical characteristics of polypoidal choroidal vasculopathy associated with chronic central serous chorioretionopathy. Korean J. Ophthalmol.: KJO 2012, 26, 15–20.
81. Fung, A.T.; Yannuzzi, L.A.; Freund, K.B. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012, 32, 1829–1837.
82. Park, S.J.; Kim, B.H.; Park, K.H.; Woo, S.J. Punctate hyperfluorescence spot as a common choroidopathy of central serous chorioretinopathy and polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2014, 158, 1155–1163.
83. Sasahara, M.; Tsujikawa, A.; Musashi, K.; Gotoh, N.; Otani, A.; Mandai, M.; Yoshimura, N. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am. J. Ophthalmol. 2006, 142, 601–607.
84. Iida, T.; Kishi, S.; Hagimura, N.; Shimizu, K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999, 19, 508–512.
85. Menchini, U.; Virgili, G.; Lanzetta, P.; Ferrari, E. Indocyanine green angiography in central serous chorioretinopathy. ICG angiography in CSC. Int. Ophthalmol. 1997, 21, 57–69.
86. Tsujikawa, A.; Ojima, Y.; Yamashiro, K.; Ooto, S.; Tamura, H.; Nakagawa, S.; Yoshimura, N. Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography. Retina 2010, 30, 801–809.
87. Imamura, Y.; Fujiwara, T.; Spaide, R.F. Fundus autofluorescence and visual acuity in central serous chorioretinopathy. Ophthalmology 2011, 118, 700–705.
88. Yamagishi, T.; Koizumi, H.; Yamazaki, T.; Kinoshita, S. Fundus autofluorescence in polypoidal choroidal vasculopathy. Ophthalmology 2012, 119, 1650–1657.
89. Ahuja, R.M.; Downes, S.M.; Stanga, P.E.; Koh, A.H.; Vingerling, J.R.; Bird, A.C. Polypoidal choroidal vasculopathy and central serous chorioretinopathy. Ophthalmology 2001, 108, 1009–1010.
90. Koizumi, H.; Yamagishi, T.; Yamazaki, T.; Kinoshita, S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am. J. Ophthalmol. 2013, 155, 305–313.
91. Jirarattanasopa, P.; Ooto, S.; Tsujikawa, A.; Yamashiro, K.; Hangai, M.; Hirata, M.; Matsumoto, A.; Yoshimura, N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012, 119, 1666–1678.
92. Cheng, C.Y.; Yamashiro, K.; Jia Chen, L.; Ahn, J.; Huang, L.; Huang, L.; Cheung, C.M.; Miyake, M.; Cackett, P.D.; Yeo, I.Y.; et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat. Commun. 2015, 6, doi:10.1038/ncomms7063.
93. Fritsche, L.G.; Chen, W.; Schu, M.; Yaspan, B.L.; Yu, Y.; Thorleifsson, G.; Zack, D.J.; Arakawa, S.; Cipriani, V.; Ripke, S.; et al. Seven new loci associated with age-related macular degeneration. Nat. Genet. 2013, 45, 433–439.
94. Liu, K.; Chen, L.J.; Lai, T.Y.; Tam, P.O.; Ho, M.; Chiang, S.W.; Liu, D.T.; Young, A.L.; Yang, Z.; Pang, C.P. Genes in the high-density lipoprotein metabolic pathway in age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology 2014, 121, 911–916.
95. Nakata, I.; Yamashiro, K.; Kawaguchi, T.; Gotoh, N.; Nakanishi, H.; Akagi-Kurashige, Y.; Miyake, M.; Tsujikawa, A.; Oishi, A.; Saito, M.; et al. Association between the cholesteryl ester transfer protein gene and polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54, 6068–6073.
96. Zhang, X.; Li, M.; Wen, F.; Zuo, C.; Chen, H.; Wu, K.; Zeng, R. Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population. Exp. Eye Res. 2013, 108, 16–22.
97. Chen, H.; Liu, K.; Chen, L.J.; Hou, P.; Chen, W.; Pang, C.P. Genetic associations in polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Mol. Vis. 2012, 18, 816–829.
98. Gotoh, N.; Yamada, R.; Nakanishi, H.; Saito, M.; Iida, T.; Matsuda, F.; Yoshimura, N. Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population. Clin. Exp. Ophthalmol. 2008, 36, 437–442.
99. Wang, Z.Y.; Zhao, K.; Zheng, J.; Rossmiller, B.; Ildefonso, C.; Biswal, M.; Zhao, P.Q. Systematic review and meta-analysis of the association between complement factor H I62V polymorphism and risk of polypoidal choroidal vasculopathy in Asian populations. PLoS ONE 2014, 9, e88324.
100. Yuan, D.; Yuan, D.; Yuan, S.; Liu, Q. The age-related maculopathy susceptibility 2 polymorphism and polypoidal choroidal vasculopathy in Asian populations: A meta-analysis. Ophthalmology 2013, 120, 2051–2057.
101. Tanaka, K.; Nakayama, T.; Mori, R.; Sato, N.; Kawamura, A.; Mizutani, Y.; Yuzawa, M. Associations of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes with subtypes of polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52, 7441–7444.
102. Tsujikawa, A.; Sasahara, M.; Otani, A.; Gotoh, N.; Kameda, T.; Iwama, D.; Yodoi, Y.; Tamura, H.; Mandai, M.; Yoshimura, N. Pigment epithelial detachment in polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2007, 143, 102–111.
103. Sakurada, Y.; Kubota, T.; Imasawa, M.; Mabuchi, F.; Tanabe, N.; Iijima, H. Association of loc387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2010, 30, 1616–1621.
104. Nakata, I.; Yamashiro, K.; Yamada, R.; Gotoh, N.; Nakanishi, H.; Hayashi, H.; Tsujikawa, A.; Otani, A.; Ooto, S.; Tamura, H.; et al. Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy. Ophthalmology 2011, 118, 1408–1415.
105. Yamashiro, K.; Tomita, K.; Tsujikawa, A.; Nakata, I.; Akagi-Kurashige, Y.; Miyake, M.; Ooto, S.; Tamura, H.; Yoshimura, N. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am. J. Ophthalmol. 2012, 154, 125–136.
106. Park, D.H.; Kim, I.T. Loc387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Retina 2012, 32, 299–307.
107. Uyama, M.; Matsubara, T.; Fukushima, I.; Matsunaga, H.; Iwashita, K.; Nagai, Y.; Takahashi, K. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch. Ophthalmol. 1999, 117, 1035–1042.
108. Yannuzzi, L.A.; Sorenson, J.; Spaide, R.F.; Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990, 10, 1–8.
109. Yannuzzi, L.A.; Wong, D.W.; Sforzolini, B.S.; Goldbaum, M.; Tang, K.C.; Spaide, R.F.; Freund, K.B.; Slakter, J.S.; Guyer, D.R.; Sorenson, J.A.; et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch. Ophthalmol. 1999, 117, 1503–1510.
110. Uyama, M.; Wada, M.; Nagai, Y.; Matsubara, T.; Matsunaga, H.; Fukushima, I.; Takahashi, K.; Matsumura, M. Polypoidal choroidal vasculopathy: Natural history. Am. J. Ophthalmol. 2002, 133, 639–648.
111. Cheung, C.M.; Yang, E.; Lee, W.K.; Lee, G.K.; Mathur, R.; Cheng, J.; Wong, D.; Wong, T.Y.; Lai, T.Y. The natural history of polypoidal choroidal vasculopathy: A multi-center series of untreated Asian patients. Graefes Arch. Clin. Exp. Ophthalmol. 2015, doi:10.1007/s00417-015-2933-2.
112. Desmettre, T.; Devoisselle, J.M.; Mordon, S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv. Ophthalmol. 2000, 45, 15–27.
113. Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy (in Japanese). Nippon Ganka Gakkai Zasshi 2005, 109, 417–427.
114. Koh, A.; Lee, W.K.; Chen, L.J.; Chen, S.J.; Hashad, Y.; Kim, H.; Lai, T.Y.; Pilz, S.; Ruamviboonsuk, P.; Tokaji, E.; et al. Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012, 32, 1453–1464.
115. Cackett, P.; Wong, D.; Yeo, I. A classification system for polypoidal choroidal vasculopathy. Retina 2009, 29, 187–191.
116. Cheung, C.M.; Lai, T.Y.; Chen, S.J.; Chong, V.; Lee, W.K.; Htoon, H.; Ng, W.Y.; Ogura, Y.; Wong, T.Y. Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: The group experience with digital fundus photography and confocal scanning laser ophthalmoscopy. Retina 2014, 34, 2397–2406.
117. Hikichi, T.; Kitamei, H.; Shioya, S. Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2014, doi:10.1136/bjophthalmol-2014-305606.
118. Lee, W.K.; Kim, K.S.; Kim, W.; Lee, S.B.; Jeon, S. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters. Am. J. Ophthalmol. 2012, 154, 355–365.
119. Tan, C.S.; Ngo, W.K.; Lim, L.W.; Lim, T.H. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes. Br. J. Ophthalmol. 2014, 98, 1528–1533.
120. Sonoda, S.; Sakamoto, T.; Otsuka, H.; Yoshinaga, N.; Yamashita, T.; Ki, I.Y.; Okubo, A.; Yamashita, T.; Arimura, N. Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC Ophthalmol. 2013, 13, doi:10.1186/1471-2415-13-43.
121. Cho, H.J.; Kim, H.S.; Jang, Y.S.; Han, J.I.; Lew, Y.J.; Lee, T.G.; Kim, C.G.; Kim, J.W. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 156, 1192–1200.
122. Byeon, S.H.; Lew, Y.J.; Lee, S.C.; Kwon, O.W. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy. Acta Ophthalmol. 2010, 88, 660–668.
123. Tsujikawa, A.; Ojima, Y.; Yamashiro, K.; Nakata, I.; Ooto, S.; Tamura, H.; Nakanishi, H.; Hayashi, H.; Otani, A.; Yoshimura, N. Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2011, 151, 961–972.
124. Ueta, T.; Iriyama, A.; Francis, J.; Takahashi, H.; Adachi, T.; Obata, R.; Inoue, Y.; Tamaki, Y.; Yanagi, Y. Development of typical age-related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age-related macular degeneration. Am. J. Ophthalmol. 2008, 146, 96–101.
125. Yamagishi, T.; Koizumi, H.; Yamazaki, T.; Kinoshita, S. Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2014, 98, 780–784.
126. Iijima, H.; Imai, M.; Gohdo, T.; Tsukahara, S. Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 1999, 127, 301–305.
127. Iijima, H.; Iida, T.; Imai, M.; Gohdo, T.; Tsukahara, S. Optical coherence tomography of orange-red subretinal lesions in eyes with idiopathic polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2000, 129, 21–26.
128. Sato, T.; Kishi, S.; Watanabe, G.; Matsumoto, H.; Mukai, R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 2007, 27, 589–594.
129. Kim, J.H.; Kang, S.W.; Kim, T.H.; Kim, S.J.; Ahn, J. Structure of polypoidal choroidal vasculopathy studied by colocalization between tomographic and angiographic lesions. Am. J. Ophthalmol. 2013, 156, 974–980.
130. De Salvo, G.; Vaz-Pereira, S.; Keane, P.A.; Tufail, A.; Liew, G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2014, 158, 1228–1238.
131. Alasil, T.; Ferrara, D.; Adhi, M.; Brewer, E.; Kraus, M.F.; Baumal, C.R.; Hornegger, J.; Fujimoto, J.G.; Witkin, A.J.; Reichel, E.; et al. En face imaging of the choroid in polypoidal choroidal vasculopathy using swept-source optical coherence tomography. Am. J. Ophthalmol. 2015, 159, 634–643.
132. Nagase, S.; Miura, M.; Makita, S.; Iwasaki, T.; Goto, H.; Yasuno, Y. High-penetration optical coherence tomography with enhanced depth imaging of polypoidal choroidal vasculopathy. Ophthalmic Surg. Lasers Imaging 2012, 43, e5–e9.
133. Sayanagi, K.; Gomi, F.; Ikuno, Y.; Akiba, M.; Nishida, K. Comparison of spectral-domain and high-penetration oct for observing morphologic changes in age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252, 3–9.
134. Sayanagi, K.; Gomi, F.; Akiba, M.; Sawa, M.; Hara, C.; Nishida, K. En-face high-penetration optical coherence tomography imaging in polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2015, 99, 29–35.
135. Leitgeb, R.A.; Werkmeister, R.M.; Blatter, C.; Schmetterer, L. Doppler optical coherence tomography. Progr. Retin. Eye Res. 2014, 41, 26–43.
136. Hong, Y.J.; Miura, M.; Makita, S.; Ju, M.J.; Lee, B.H.; Iwasaki, T.; Yasuno, Y. Noninvasive investigation of deep vascular pathologies of exudative macular diseases by high-penetration optical coherence angiography. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3621–3631.
137. Zeng, R.; Zhang, X.; Su, Y.; Li, M.; Wu, K.; Wen, F. The noninvasive retro-mode imaging modality of confocal scanning laser ophthalmoscopy in polypoidal choroidal vasculopathy: A preliminary application. PLoS ONE 2013, 8, e75711.
138. Pilotto, E.; Sportiello, P.; Alemany-Rubio, E.; Vujosevic, S.; Segalina, S.; Fregona, I.; Midena, E. Confocal scanning laser ophthalmoscope in the retromode imaging modality in exudative age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251, 27–34.
139. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch. Ophthalmol. 1991, 109, 1109–1114.
140. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. 1982, 100, 912–918.
141. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. 1990, 108, 816–824.
142. Macular Photocoagulation Study Group. Evaluation of argon green vs. krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the macular photocoagulation study. Arch. Ophthalmol. 1994, 112, 1176–1184.
143. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch. Ophthalmol. 1993, 111, 1200–1209.
144. Cheung, C.M.G.; Yeo, I.; Li, X.; Mathur, R.; Lee, S.Y.; Chan, C.M.; Wong, D.; Wong, T.Y. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 155, 295–304.
145. Spaide, R.F.; Donsoff, I.; Lam, D.L.; Yannuzzi, L.A.; Jampol, L.M.; Slakter, J.; Sorenson, J.; Freund, K.B. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002, 22, 529–535.
146. Oishi, A.; Kojima, H.; Mandai, M.; Honda, S.; Matsuoka, T.; Oh, H.; Kita, M.; Nagai, T.; Fujihara, M.; Bessho, N.; et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am. J. Ophthalmol. 2013, 156, 644–651.
147. Rouvas, A.A.; Papakostas, T.D.; Ntouraki, A.; Douvali, M.; Vergados, I.; Ladas, I.D. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011, 31, 464–474.
148. Inoue, M.; Arakawa, A.; Yamane, S.; Kadonosono, K. Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye 2013, 27, 1013–1020.
149. Lafaut, B.A.; Leys, A.M.; Snyers, B.; Rasquin, F.; de Laey, J.J. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238, 752–759.
150. Lip, P.L.; Hope-Ross, M.W.; Gibson, J.M. Idiopathic polypoidal choroidal vasculopathy: A disease with diverse clinical spectrum and systemic associations. Eye 2000, 14, 695–700.
151. Lee, M.W.; Yeo, I.; Wong, D.; Ang, C.L. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye 2009, 23, 145–148.
152. Kwok, A.K.; Lai, T.Y.; Chan, C.W.; Neoh, E.L.; Lam, D.S. Polypoidal choroidal vasculopathy in Chinese patients. Br. J. Ophthalmol. 2002, 86, 892–897.
153. Yuzawa, M.; Mori, R.; Haruyama, M. A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2003, 47, 379–384.
154. Oishi, A.; Miyamoto, N.; Mandai, M.; Honda, S.; Matsuoka, T.; Oh, H.; Kita, M.; Nagai, T.; Bessho, N.; Uenishi, M.; et al. LAPTOP study: A 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology 2014, 121, 1151–1152.
155. Kokame, G.T.; Yeung, L.; Lai, J.C. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br. J. Ophthalmol. 2010, 94, 297–301.
156. Kang, H.M.; Koh, H.J. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 156, 652–660.
157. Cho, H.J.; Han, S.Y.; Kim, H.S.; Lee, T.G.; Kim, J.W. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2015, 59, 29–35.
158. Cho, H.J.; Baek, J.S.; Lee, D.W.; Kim, C.G.; Kim, J.W. Short-term effectiveness of intravitreal bevacizumab vs. Ranibizumab injections for patients with polypoidal choroidal vasculopathy. Korean J. Ophthalmol. KJO 2012, 26, 157–162.
159. Hikichi, T.; Higuchi, M.; Matsushita, T.; Kosaka, S.; Matsushita, R.; Takami, K.; Ohtsuka, H.; Kitamei, H.; Shioya, S. Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2013, 97, 617–621.
160. Ogino, K.; Tsujikawa, A.; Yamashiro, K.; Ooto, S.; Oishi, A.; Nakata, I.; Miyake, M.; Yoshimura, N. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3771–3779.
161. Hikichi, T.; Higuchi, M.; Matsushita, T.; Kosaka, S.; Matsushita, R.; Takami, K.; Ohtsuka, H.; Ariga, H. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am. J. Ophthalmol. 2012, 154, 117–124.
162. Matsumiya, W.; Honda, S.; Kusuhara, S.; Tsukahara, Y.; Negi, A. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): Comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol. 2013, 13, 10.
163. Koizumi, H.; Yamagishi, T.; Yamazaki, T.; Kinoshita, S. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2011, 95, 1555–1559.
164. Wakabayashi, T.; Gomi, F.; Sawa, M.; Tsujikawa, M.; Nishida, K. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2012, 96, 394–399.
165. Kim, K.S.; Lee, W.K. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2011, 55, 370–377.
166. Cheng, C.K.; Peng, C.H.; Chang, C.K.; Hu, C.C.; Chen, L.J. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011, 31, 846–856.
167. Tsujikawa, A.; Ooto, S.; Yamashiro, K.; Tamura, H.; Otani, A.; Yoshimura, N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn. J. Ophthalmol. 2010, 54, 310–319.
168. Lim, J.Y.; Lee, S.Y.; Kim, J.G.; Lee, J.Y.; Chung, H.; Yoon, Y.H. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012, 90, 61–67.
169. Mitamura, Y.; Kitahashi, M.; Kubota-Taniai, M.; Yamamoto, S. Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results. Indian J. Ophthalmol. 2010, 58, 291–296.
170. Gomi, F.; Sawa, M.; Sakaguchi, H.; Tsujikawa, M.; Oshima, Y.; Kamei, M.; Tano, Y. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2008, 92, 70–73.
171. Lai, T.Y.; Chan, W.M.; Liu, D.T.; Luk, F.O.; Lam, D.S. Intravitreal bevacizumab (avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 2008, 92, 661–666.
172. Inoue, M.; Arakawa, A.; Yamane, S.; Kadonosono, K. Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy. Retina 2014, 34, 2178–2184.
173. Ijiri, S.; Sugiyama, K. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2015, 253, 351–357.
174. Oishi, A.; Tsujikawa, A.; Yamashiro, K.; Ooto, S.; Tamura, H.; Nakanishi, H.; Ueda-Arakawa, N.; Miyake, M.; Akagi-Kurashige, Y.; Hata, M.; et al. One year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am. J. Ophthalmol. 2015, 159, 853–860.
175. Chaikitmongkol, V.; Bressler, N.M. Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use. JAMA Ophthalmol. 2013, 131, 260–262.
176. Kumar, N.; Marsiglia, M.; Mrejen, S.; Fung, A.T.; Slakter, J.; Sorenson, J.; Freund, K.B. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013, 33, 1605–1612.
177. Patel, K.H.; Chow, C.C.; Rathod, R.; Mieler, W.F.; Lim, J.I.; Ulanski, L.J., 2nd; Leiderman, Y.I.; Arun, V.; Chau, F.Y. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 2013, 27, 663–667.
178. Yonekawa, Y.; Andreoli, C.; Miller, J.B.; Loewenstein, J.I.; Sobrin, L.; Eliott, D.; Vavvas, D.G.; Miller, J.W.; Kim, I.K. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am. J. Ophthalmol. 2013, 156, 29–35.
179. Cheung, C.M.; Mohla, A.; Wong, T.Y. Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to aflibercept. Eye 2014, 28, 1148–1149.
180. Saito, M.; Kano, M.; Itagaki, K.; Oguchi, Y.; Sekiryu, T. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina 2014, 34, 2192–2201.
181. Kokame, G.T. Intravitreal aflibercept injection for polypoidal choroidal vasculopathy with hemorrhage or exudation. Available online: https://clinicaltrials.gov/ct2/show/NCT01871376 (accessed on 22 August 2014).
182. Hikichi, T.; Higuchi, M.; Matsushita, T.; Kosaka, S.; Matsushita, R.; Takami, K.; Ohtsuka, H. Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Retina 2013, 33, 1949–1958.
183. Tatar, O.; Adam, A.; Shinoda, K.; Stalmans, P.; Eckardt, C.; Luke, M.; Bartz-Schmidt, K.U.; Grisanti, S. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am. J. Ophthalmol. 2006, 142, 95–104.
184. Tatar, O.; Kaiserling, E.; Adam, A.; Gelisken, F.; Shinoda, K.; Volker, M.; Lafaut, B.A.; Bartz-Schmidt, K.U.; Grisanti, S. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch. Ophthalmol. 2006, 124, 815–823.
185. Tatar, O.; Shinoda, K.; Adam, A.; Eckert, T.; Eckardt, C.; Lucke, K.; Deuter, C.; Bartz-Schmidt, K.U.; Grisanti, S. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Br. J. Ophthalmol. 2007, 91, 166–173.
186. Schmidt-Erfurth, U.; Schlotzer-Schrehard, U.; Cursiefen, C.; Michels, S.; Beckendorf, A.; Naumann, G.O. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Investig. Ophthalmol. Vis. Sci. 2003, 44, 4473–4480.
187. Lee, M.Y.; Lee, W.K.; Baek, J.; Kwon, O.W.; Lee, J.H. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor. Am. J. Ophthalmol. 2013, 156, 343–348.
188. Wang, W.; He, M.; Zhang, X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis of comparative studies. PLoS ONE 2014, 9, e110667.
189. Akaza, E.; Yuzawa, M.; Mori, R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2011, 55, 39–44.
190. Honda, S.; Kurimoto, Y.; Kagotani, Y.; Yamamoto, H.; Takagi, H.; Uenishi, M.; Hyogo Macular Disease Study Group. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan. Jpn. J. Ophthalmol. 2009, 53, 593–597.
191. Hata, M.; Mandai, M.; Kojima, H.; Kameda, T.; Miyamoto, N.; Kurimoto, Y. Five-year visual outcomes of typical age-related macular degeneration and/or polypoidal choroidal vasculopathy patients who received photodynamic therapy (PDT) as initial treatment in comparison with patients prior to the PDT era. Nippon Ganka Gakkai Zasshi 2012, 116, 937–945.
192. Jeon, S.; Lee, W.K.; Kim, K.S. Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: Results at 3 years. Retina 2013, 33, 1193–1200.
193. Kang, H.M.; Kim, Y.M.; Koh, H.J. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 155, 438–447.
194. Leal, S.; Silva, R.; Figueira, J.; Cachulo, M.L.; Pires, I.; de Abreu, J.R.; Cunha-Vaz, J.G. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: Results after 3 years of follow-up. Retina 2010, 30, 1197–1205.
195. Saito, M.; Iida, T.; Kano, M.; Itagaki, K. Five-year results of photodynamic therapy with and without supplementary antivascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252, 227–235.
196. Kang, H.M.; Koh, H.J.; Lee, C.S.; Lee, S.C. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: Long-term visual outcome. Am. J. Ophthalmol. 2014, 157, 598–606.
197. Wong, C.W.; Cheung, C.M.; Mathur, R.; Li, X.; Chan, C.M.; Wong, E.; Lee, S.Y.; Wong, D.; Wong, T.Y. Three year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: Retrospective study and systematic review. Retina 2014 (in press).
198. Gomi, F.; Sawa, M.; Wakabayashi, T.; Sasamoto, Y.; Suzuki, M.; Tsujikawa, M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2010, 150, 48–54.
199. ClinicalTrials.gov. Visual Outcome in Patients with Symptomatic Macular PCV Treated with either Ranibizumab as Monotherapy or Combined with Verteporfin Photodynamic Therapy (EVEREST II). Availiable online: http://clinicaltrials.gov/ct2/show/NCT01846273?term=everest&rank=7 (accessed on 22 August 2014).
200. ClinicalTrials.gov. Aflibercept in Polypoidal Choroidal Vasculopathy (PLANET). Availiable online: http://clinicaltrials.gov/ct2/show/NCT02120950?term=PLANET&rank=2 (accessed on 22 August 2014).
201. Yamashita, A.; Shiraga, F.; Shiragami, C.; Ono, A.; Tenkumo, K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2010, 149, 465–471.
202. Yamashita, A.; Shiraga, F.; Shiragami, C.; Shirakata, Y.; Fujiwara, A. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 155, 96–102.
203. Fan, N.W.; Lau, L.I.; Chen, S.J.; Yang, C.S.; Lee, F.L. Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy. J. Chin. Med. Assoc. JCMA 2014, 77, 101–107.
204. Ricci, F.; Calabrese, A.; Regine, F.; Missiroli, F.; Ciardella, A.P. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina 2012, 32, 1280–1288.
205. Sagong, M.; Lim, S.; Chang, W. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2012, 153, 873–882.
206. Sakurai, M.; Baba, T.; Kitahashi, M.; Yokouchi, H.; Kubota-Taniai, M.; Bikbova, G.; Oshitari, T.; Yamamoto, S. One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Clin. Ophthalmol. 2014, 8, 235–241.
207. Yoshida, Y.; Kohno, T.; Yamamoto, M.; Yoneda, T.; Iwami, H.; Shiraki, K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn. J. Ophthalmol. 2013, 57, 283–293.
208. Friedman, W.A.; Bova, F.J. Radiosurgery for arteriovenous malformations. Neurol. Res. 2011, 33, 803–819.
209. Jackson, T.L.; Chakravarthy, U.; Kaiser, P.K.; Slakter, J.S.; Jan, E.; Bandello, F.; O’Shaughnessy, D.; Gertner, M.E.; Danielson, L.; Moshfeghi, D.M.; et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the intrepid study. Ophthalmology 2013, 120, 1893–1900.
210. Jackson, T.L.; Chakravarthy, U.; Slakter, J.S.; Muldrew, A.; Shusterman, E.M.; O’Shaughnessy, D.; Arnoldussen, M.; Gertner, M.E.; Danielson, L.; Moshfeghi, D.M.; et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: Year 2 results of the INTREPID study. Ophthalmology 2014, 122, 138–145.
211. Introini, U.; Casalino, G.; Triolo, G.; O’Shaughnessy, D.; Shusterman, E.M.; Chakravarthy, U.; Slakter, J.S.; Bandello, F. Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study. Ophthalmologica 2015, 232, 82–88.
212. Jackson, T.L.; Dugel, P.U.; Bebchuk, J.D.; Smith, K.R.; Petrarca, R.; Slakter, J.S.; Jaffe, G.J.; Nau, J.A.; Group, C.S. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): Fluorescein angiography and optical coherence tomography. Ophthalmology 2013, 120, 1597–1603.
213. Petrarca, R.; Dugel, P.U.; Bennett, M.; Barak, A.; Weinberger, D.; Nau, J.; Jackson, T.L. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): Month 24 safety and efficacy results. Retina 2014, 34, 874–879.
214. Petrarca, R.; Dugel, P.U.; Nau, J.; Slakter, J.S.; Jaffe, G.J.; Jackson, T.L. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): Month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013, 120, 328–333.
215. Dugel, P.U.; Petrarca, R.; Bennett, M.; Barak, A.; Weinberger, D.; Nau, J.; Jackson, T.L. Macular epiretinal brachytherapy in treated age-related macular degeneration: Meritage study: Twelve-month safety and efficacy results. Ophthalmology 2012, 119, 1425–1431.
216. Dugel, P.U.; Bebchuk, J.D.; Nau, J.; Reichel, E.; Singer, M.; Barak, A.; Binder, S.; Jackson, T.L.; Group, C.S. Epimacular brachytherapy for neovascular age-related macular degeneration: A randomized, controlled trial (CABERNET). Ophthalmology 2013, 120, 317–327.
217. Van Zeeburg, E.J.; van Meurs, J.C. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica 2013, 229, 1–14.
218. Steel, D.H.; Sandhu, S.S. Submacular haemorrhages associated with neovascular age-related macular degeneration. Br. J. Ophthalmol. 2011, 95, 1051–1057.
219. Kim, J.H.; Chang, Y.S.; Kim, J.W.; Kim, C.G.; Yoo, S.J.; Cho, H.J. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology 2014, 121, 926–935.
220. Cho, H.J.; Koh, K.M.; Kim, H.S.; Lee, T.G.; Kim, C.G.; Kim, J.W. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2013, 156, 524–531.
221. Chang, M.A.; do, D.V.; Bressler, S.B.; Cassard, S.D.; Gower, E.W.; Bressler, N.M. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 2010, 30, 1171–1176.
222. Stifter, E.; Michels, S.; Prager, F.; Georgopoulos, M.; Polak, K.; Hirn, C.; Schmidt-Erfurth, U. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am. J. Ophthalmol. 2007, 144, 886–892.
223. Bressler, N.M.; Bressler, S.B.; Hawkins, B.S.; Marsh, M.J.; Sternberg, P., Jr.; Thomas, M.A. Submacular Surgery Trials Pilot Study, I. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am. J. Ophthalmol. 2000, 130, 387–407.
224. Hawkins, B.S.; Bressler, N.M.; Bressler, S.B.; Davidorf, F.H.; Hoskins, J.C.; Marsh, M.J.; Miskala, P.H.; Redford, M.; Sternberg, P., Jr.; Thomas, M.A.; et al. Surgical removal vs. observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: Sst Report No. 9. Arch. Ophthalmol. 2004, 122, 1597–1611.
225. Romano, M.R.; Valldeperas, X.; Vinciguerra, P.; Wong, D. Sub-macular surgery: Is still an option for age-related macular degeneration? Curr. Drug Targets 2011, 12, 190–198.
226. Dang, Y.; Zhang, C.; Zhu, Y. Stem cell therapies for age-related macular degeneration: The past, present, and future. Clin. Interv. Aging 2015, 10, 255–264.
227. Schwartz, S.D.; Regillo, C.D.; Lam, B.L.; Eliott, D.; Rosenfeld, P.J.; Gregori, N.Z.; Hubschman, J.P.; Davis, J.L.; Heilwell, G.; Spirn, M.; et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet 2015, 385, 509–516.